{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:52:16Z","timestamp":1794433936795,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Research Council","award":["ERC 787925"],"award-info":[{"award-number":["ERC 787925"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81874229 and 8207100977"],"award-info":[{"award-number":["81874229 and 8207100977"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver cancer is one of the most commonly diagnosed cancers and the fourth leading cause of cancer-related death worldwide. Broad-spectrum kinase inhibitors like sorafenib and lenvatinib provide only modest survival benefit to patients with hepatocellular carcinoma (HCC). This study aims to identify novel therapeutic strategies for HCC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Integrated bioinformatics analyses and a non-biased CRISPR loss of function genetic screen were performed to identify potential therapeutic targets for HCC cells. Whole-transcriptome sequencing (RNA-Seq) and time-lapse live imaging were performed to explore the mechanisms of the synergy between CDC7 inhibition and ATR or CHK1 inhibitors in HCC cells. Multiple in vitro and in vivo assays were used to validate the synergistic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Through integrated bioinformatics analyses using the Cancer Dependency Map and the TCGA database, we identified ATR-CHK1 signaling as a therapeutic target for liver cancer. Pharmacological inhibition of ATR or CHK1 leads to robust proliferation inhibition in liver cancer cells having a high basal level of replication stress. For liver cancer cells that are resistant to ATR or CHK1 inhibition, treatment with CDC7 inhibitors induces strong DNA replication stress and consequently such drugs show striking synergy with ATR or CHK1 inhibitors. The synergy between ATR-CHK1 inhibition and CDC7 inhibition probably derives from abnormalities in mitosis inducing mitotic catastrophe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data highlights the potential of targeting ATR-CHK1 signaling, either alone or in combination with CDC7 inhibition, for the treatment of liver cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-021-00981-0","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T18:28:11Z","timestamp":1634581691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Yuchen","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Benedict","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"van Gemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"Lieftink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick L.","family":"Beijersbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"te Riele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-3423","authenticated-orcid":false,"given":"Ren\u00e9","family":"Bernards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"15","key":"981_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"4","key":"981_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"10126","key":"981_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet."},{"issue":"10064","key":"981_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366.","journal-title":"Lancet."},{"issue":"1","key":"981_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54\u201363.","journal-title":"N Engl J Med"},{"issue":"3","key":"981_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193\u2013202.","journal-title":"J Clin Oncol"},{"issue":"10088","key":"981_CR7","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet."},{"key":"981_CR8","doi-asserted-by":"publisher","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","volume":"30","author":"T Yau","year":"2019","unstructured":"Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874\u20135.","journal-title":"Ann Oncol"},{"issue":"2","key":"981_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","volume":"72","author":"S Faivre","year":"2020","unstructured":"Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020;72(2):342\u201352.","journal-title":"J Hepatol"},{"issue":"1","key":"981_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"20","key":"981_CR11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"9","key":"981_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona E, Fernandez-Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18(9):586\u201395.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"981_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"981_CR14","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-12-1322","volume":"18","author":"MI Walton","year":"2012","unstructured":"Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res. 2012;18(20):5650\u201361.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"981_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/1535-7163.MCT-09-0938","volume":"9","author":"MI Walton","year":"2010","unstructured":"Walton MI, Eve PD, Hayes A, Valenti M, De Haven BA, Box G, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther. 2010;9(1):89\u2013100.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"981_CR16","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","volume":"73","author":"CJ Huntoon","year":"2013","unstructured":"Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013;73(12):3683\u201391.","journal-title":"Cancer Res"},{"issue":"12","key":"981_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nsmb.2189","volume":"18","author":"M Murga","year":"2011","unstructured":"Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Monta\u00f1a MF, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011;18(12):1331\u20135.","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"981_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nsmb.2076","volume":"18","author":"LI Toledo","year":"2011","unstructured":"Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol. 2011;18(6):721\u20137.","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"981_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011;7(7):428\u201330.","journal-title":"Nat Chem Biol"},{"issue":"23","key":"981_CR20","doi-asserted-by":"publisher","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","volume":"70","author":"O Gilad","year":"2010","unstructured":"Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010;70(23):9693\u2013702.","journal-title":"Cancer Res"},{"key":"981_CR21","doi-asserted-by":"publisher","first-page":"9357","DOI":"10.1038\/srep09357","volume":"5","author":"MT Weng","year":"2015","unstructured":"Weng MT, Tung TH, Lee JH, Wei SC, Lin HL, Huang YJ, et al. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. Sci Rep. 2015;5:9357.","journal-title":"Sci Rep"},{"issue":"6","key":"981_CR22","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1172\/JCI61380","volume":"122","author":"J Hong","year":"2012","unstructured":"Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen G, et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest. 2012;122(6):2165\u201375.","journal-title":"J Clin Invest"},{"issue":"1","key":"981_CR23","doi-asserted-by":"publisher","first-page":"e000340","DOI":"10.1136\/jitc-2019-000340","volume":"8","author":"H Sheng","year":"2020","unstructured":"Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer. 2020;8(1):e000340.","journal-title":"J Immunother Cancer"},{"issue":"18","key":"981_CR24","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-10-0185","volume":"16","author":"A Montagnoli","year":"2010","unstructured":"Montagnoli A, Moll J, Colotta F. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res. 2010;16(18):4503\u20138.","journal-title":"Clin Cancer Res"},{"issue":"7777","key":"981_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-019-1607-3","volume":"574","author":"C Wang","year":"2019","unstructured":"Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature. 2019;574(7777):268\u201372.","journal-title":"Nature."},{"issue":"15_suppl","key":"981_CR26","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1200\/JCO.2018.36.15_suppl.2506","volume":"36","author":"T Shimizu","year":"2018","unstructured":"Shimizu T, Doi T, Kondo S, Takahashi H, Yamamoto N, Sheldon-Waniga E, et al. First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):2506.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"981_CR27","doi-asserted-by":"publisher","first-page":"TPS3167","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3167","volume":"37","author":"PF Gallagher","year":"2019","unstructured":"Gallagher PF, Coyle V, Evans TRJ, Plummer ER, Clive S, McGuigan L, et al. A CRUK first-in-human phase I trial of a CDC7 inhibitor, LY3143921 hydrate, in patients with advanced solid tumors. J Clin Oncol. 2019;37(15_suppl):TPS3167.","journal-title":"J Clin Oncol"},{"issue":"5","key":"981_CR28","doi-asserted-by":"publisher","first-page":"eaav3660","DOI":"10.1126\/sciadv.aav3660","volume":"5","author":"K Iwai","year":"2019","unstructured":"Iwai K, Nambu T, Dairiki R, Ohori M, Yu J, Burke K, et al. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. Sci Adv. 2019;5(5):eaav3660.","journal-title":"Sci Adv"},{"issue":"9","key":"981_CR29","doi-asserted-by":"publisher","first-page":"108096","DOI":"10.1016\/j.celrep.2020.108096","volume":"32","author":"MD Rainey","year":"2020","unstructured":"Rainey MD, Bennett D, O'Dea R, Zanchetta ME, Voisin M, Seoighe C, et al. ATR restrains DNA synthesis and mitotic catastrophe in response to CDC7 inhibition. Cell Rep. 2020;32(9):108096.","journal-title":"Cell Rep"},{"issue":"6","key":"981_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.3536","volume":"34","author":"B Evers","year":"2016","unstructured":"Evers B, Jastrzebski K, Heijmans JP, Grernrum W, Beijersbergen RL, Bernards R. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat Biotechnol. 2016;34(6):631\u20133.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"981_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics."},{"issue":"10","key":"981_CR32","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41(10):e108.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"981_CR33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1053\/j.gastro.2011.12.039","volume":"142","author":"S Roessler","year":"2012","unstructured":"Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 2012;142(4):957\u2013966.e912.","journal-title":"Gastroenterology"},{"issue":"7","key":"981_CR34","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"A Ally","year":"2017","unstructured":"Ally A, Balasundaram M, Carlsen R, Chuah E, Clarke A, Dhalla N, et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327\u20131341. e1323.","journal-title":"Cell"},{"issue":"5","key":"981_CR35","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.cell.2019.10.038","volume":"179","author":"Q Gao","year":"2019","unstructured":"Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019;179(5):1240.","journal-title":"Cell."},{"issue":"Database issue","key":"981_CR36","doi-asserted-by":"publisher","first-page":"D562","DOI":"10.1093\/nar\/gki022","volume":"33","author":"T Barrett","year":"2005","unstructured":"Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, et al. NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res. 2005;33(Database issue):D562\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"981_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400\u2013416.e411.","journal-title":"Cell"},{"issue":"3","key":"981_CR38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166(3):740\u201354.","journal-title":"Cell."},{"issue":"2","key":"981_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Can. 2020;1(2):235\u201348.","journal-title":"Nat Can"},{"issue":"12","key":"981_CR40","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49(12):1779\u201384.","journal-title":"Nat Genet"},{"issue":"12","key":"981_CR41","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739\u201340.","journal-title":"Bioinformatics."},{"issue":"5","key":"981_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS."},{"key":"981_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"12","key":"981_CR44","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics."},{"issue":"5507","key":"981_CR45","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1126\/science.1056154","volume":"291","author":"RD Wood","year":"2001","unstructured":"Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001;291(5507):1284\u20139.","journal-title":"Science."},{"issue":"2","key":"981_CR46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrc2998","volume":"11","author":"SS Lange","year":"2011","unstructured":"Lange SS, Takata K, Wood RD. DNA polymerases and cancer. Nat Rev Cancer. 2011;11(2):96\u2013110.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"981_CR47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across the Cancer Genome Atlas. Cell Rep. 2018;23(1):239\u2013254.e236.","journal-title":"Cell Rep"},{"issue":"6","key":"981_CR48","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","volume":"59","author":"R Buisson","year":"2015","unstructured":"Buisson R, Boisvert JL, Benes CH, Zou L. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase. Mol Cell. 2015;59(6):1011\u201324.","journal-title":"Mol Cell"},{"issue":"7","key":"981_CR49","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/acschembio.7b00117","volume":"12","author":"MD Rainey","year":"2017","unstructured":"Rainey MD, Quachthithu H, Gaboriau D, Santocanale C. DNA replication dynamics and cellular responses to ATP competitive CDC7 kinase inhibitors. ACS Chem Biol. 2017;12(7):1893\u2013902.","journal-title":"ACS Chem Biol"},{"issue":"4","key":"981_CR50","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307\u201320.","journal-title":"Nat Rev Drug Discov"},{"issue":"7753","key":"981_CR51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Gon\u00e7alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568(7753):511\u20136.","journal-title":"Nature."},{"issue":"7753","key":"981_CR52","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","volume":"568","author":"EM Chan","year":"2019","unstructured":"Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568(7753):551\u20136.","journal-title":"Nature."},{"issue":"9","key":"981_CR53","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41588-018-0191-z","volume":"50","author":"AD Durbin","year":"2018","unstructured":"Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018;50(9):1240\u20136.","journal-title":"Nat Genet"},{"issue":"7","key":"981_CR54","doi-asserted-by":"publisher","first-page":"e9405","DOI":"10.15252\/msb.20199405","volume":"16","author":"E Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves E, Segura-Cabrera A, Pacini C, Picco G, Behan FM, Jaaks P, et al. Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. Mol Syst Biol. 2020;16(7):e9405.","journal-title":"Mol Syst Biol"},{"issue":"2","key":"981_CR55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000504548","volume":"9","author":"CM Kim","year":"2020","unstructured":"Kim CM, Hwang S, Keam B, Yu YS, Kim JH, Kim DS, et al. Gene signature for sorafenib susceptibility in hepatocellular carcinoma: different approach with a predictive biomarker. Liver Cancer. 2020;9(2):182\u201392.","journal-title":"Liver Cancer"},{"issue":"5","key":"981_CR56","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25(5):751\u20138.","journal-title":"Nat Med"},{"issue":"8","key":"981_CR57","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717\u201329.","journal-title":"N Engl J Med"},{"key":"981_CR58","doi-asserted-by":"publisher","unstructured":"Buus R, Sestak I, Kronenwett R, Ferree S, Schnabel CA, Baehner FL, et al. Molecular drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: a TransATAC study. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.20.00853.","DOI":"10.1200\/JCO.20.00853"},{"issue":"5","key":"981_CR59","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","volume":"155","author":"LI Toledo","year":"2013","unstructured":"Toledo LI, Altmeyer M, Rask MB, Lukas C, Larsen DH, Povlsen LK, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell. 2013;155(5):1088\u2013103.","journal-title":"Cell."},{"issue":"4","key":"981_CR60","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.celrep.2013.10.027","volume":"5","author":"JK Eykelenboom","year":"2013","unstructured":"Eykelenboom JK, Harte EC, Canavan L, Pastor-Peidro A, Calvo-Asensio I, Llorens-Agost M, et al. ATR activates the S-M checkpoint during unperturbed growth to ensure sufficient replication prior to mitotic onset. Cell Rep. 2013;5(4):1095\u2013107.","journal-title":"Cell Rep"},{"issue":"4","key":"981_CR61","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1016\/S0960-9822(01)00057-4","volume":"11","author":"CE Canman","year":"2001","unstructured":"Canman CE. Replication checkpoint: preventing mitotic catastrophe. Curr Biol. 2001;11(4):R121\u20134.","journal-title":"Curr Biol"},{"issue":"6","key":"981_CR62","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/onc.2012.72","volume":"32","author":"K Brooks","year":"2013","unstructured":"Brooks K, Oakes V, Edwards B, Ranall M, Leo P, Pavey S, et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene. 2013;32(6):788\u201396.","journal-title":"Oncogene."},{"issue":"8","key":"981_CR63","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1073\/pnas.1012351108","volume":"108","author":"KA Cole","year":"2011","unstructured":"Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011;108(8):3336\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"981_CR64","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","volume":"35","author":"Y Fang","year":"2019","unstructured":"Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, et al. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell. 2019;35(6):851\u2013867.e857.","journal-title":"Cancer Cell"},{"key":"981_CR65","volume-title":"CDC7 inhibition in PLC\/PRF\/5 cells. GSE183751, Gene Expression Omnibus","author":"C Wang","year":"2021","unstructured":"Wang C. CDC7 inhibition in PLC\/PRF\/5 cells. GSE183751, Gene Expression Omnibus. 2021. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE183751."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-021-00981-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-021-00981-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-021-00981-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T19:19:10Z","timestamp":1634584750000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-021-00981-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1186\/s13073-021-00981-0","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"25 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal work was approved by Shanghai Cancer Institute and performed according to relevant guidelines by the Shanghai Medical Experimental Animal Care Commission and Shanghai Cancer Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}